When is the scheduled conference call for Accelerate Diagnostics to review their third-quarter results?

The conference call will take place on Thursday, November 7, 2024, at 4:30 p.m. Eastern Time.

How can interested parties listen to the conference call?

Investors can listen to the audio webcast online at ir.axdx.com or by phone by dialing +1.877.883.0383 in the U.S. or +1.412.902.6506 internationally.

How long will the replay of the conference call be available?

The call will be available for replay by telephone until November 28, 2024, using the replay code 2603705.

What is the primary focus of Accelerate Diagnostics, Inc.?

Accelerate Diagnostics, Inc. is focused on providing solutions to combat antibiotic resistance and sepsis through in vitro diagnostics.

What advancements do Accelerate's products offer in terms of antibiotic susceptibility testing?

The Accelerate Pheno system and associated testing kits aim to provide results 1-2 days faster than traditional methods, improving antibiotic therapy optimization for patients.

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results

10/25/24 4:30:00 PM ET

$AXDX

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $AXDX alert in real time by email

TUCSON, Ariz., Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m. Eastern Time to review 2024 third quarter results.

To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days.

To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 1269422. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 2603705 until November 28, 2024.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. In addition to the Accelerate Arc system, the Accelerate Pheno system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA-cleared Accelerate Pheno system and Accelerate PhenoTest BC kit fully automate sample preparation, identification and phenotypic antibiotic susceptibility testing in approximately seven hours directly from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier. The FDA-cleared Accelerate Arc and BC kit platform is an automated positive blood culture sample preparation platform for use with Bruker's MALDI Biotyper® CA System (MBT-CA System) and MBT-CA Sepsityper® software extension.

© Copyright 2024 Accelerate Diagnostics, Inc. All Rights Reserved. The "ACCELERATE DIAGNOSTICS," "ACCELERATE PHENO," "ACCELERATE PHENOTEST," "ACCELERATE ARC" and "ACCELERATE WAVE" diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc. All other trademarks are the property of their respective owners.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2024-third-quarter-results-302287696.html

SOURCE Accelerate Diagnostics, Inc.

Get the next $AXDX alert in real time by email

Date	Price Target	Rating	Analyst
3/9/2022	$5.00	Buy → Hold	Craig-Hallum

Date

Price Target

Rating

Analyst

3/9/2022

$5.00

Buy → Hold

Craig-Hallum

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results

Chat with this insight

Q&A

When is the scheduled conference call for Accelerate Diagnostics to review their third-quarter results?

How can interested parties listen to the conference call?

How long will the replay of the conference call be available?

What is the primary focus of Accelerate Diagnostics, Inc.?

What advancements do Accelerate's products offer in terms of antibiotic susceptibility testing?

Recent Analyst Ratings for $AXDX

$AXDX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Strobeck Matthew bought 100,000 shares (SEC Form 4)

Francesconi Louise bought 13,333 shares, increasing direct ownership by 176% to 20,927 units (SEC Form 4)

Massarany Hany bought 16,666 shares, increasing direct ownership by 219% to 24,260 units (SEC Form 4)

$AXDX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

SEC Form SC 13D/A filed by Accelerate Diagnostics Inc. (Amendment)

SEC Form SC 13G filed by Accelerate Diagnostics Inc.

$AXDX Press Releases

Fastest customizable press release news feed in the world

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results